Drug Trial Radar · NCT06508684
Current Status of BTKi Treatment for CLL/SLL in China
Last checked: Nov 20, 2026Latest source record: Jul 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,000
Planned (sponsor's estimate)
Start
Jul 13, 2024
Primary completion
Feb 12, 2025
Study completion Jul 12, 2025
Sponsor
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 18, 2024
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
BTKi has become the standard treatment regimen for CLL/SLL,there is a lack of large-scale real-world studies on the use status and related influencing factors of BTK inhibitors. Therefore, we plan to conduct this multicenter retrospective cross-sectional study to understand the current situation of BTK inhibitor treatment for CLL/SLL patients in China and the related influencing factors, and to explore more suitable treatment patterns based on this.
Conditions
- CLL/SLL
Interventions
BTK inhibitorDrug
BTKi can refer to Orelabrutinib, Ibrutinib, Zanubrutinib, and Acalabrutinib
Primary outcomes
What the sponsor says the trial is designed to measure.
- Patient characteristics of those receiving BTKi treatmentTime frame: up to one year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
Nanjin, Jiangsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.